Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer

NCT04786964 is registered in ClinicalTrials.gov with Checkpoint Therapeutics, Inc. as lead sponsor.

NCT NCT04786964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04786964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer
Lead sponsor
Checkpoint Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
December 8, 2021
Completion date
December 30, 2023
Enrollment
25 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-squamous non small cell lung cancer